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ABSTRACT
Increasing numbers of people living with HIV (PLHIV) in sub-Saharan Africa
are experiencing failure of ﬁrst-line antiretroviral therapy and transitioning
onto second-line regimens. However, there is a dearth of research on their
treatment experiences. We conducted in-depth interviews with 43 PLHIV
on second- or third-line antiretroviral therapy and 15 HIV health workers
in Kenya, Malawi and Mozambique to explore patients’ and health
workers’ perspectives on these transitions. Interviews were audio-
recorded, transcribed and translated into English. Data were coded
inductively and analysed thematically. In all settings, experiences of
treatment failure and associated episodes of ill-health disrupted daily
social and economic activities, and recalled earlier fears of dying from
HIV. Transitioning onto more eﬀective regimens often represented a
second (or third) chance to (re-)engage with HIV care, with patients
prioritising their health over other aspects of their lives. However, many
patients struggled to maintain these transformations, particularly when
faced with persistent social challenges to pill-taking, alongside the
burden of more complex regimens and an inability to mobilise suﬃcient
resources to accommodate change. Eﬀorts to identify treatment failure
and support regimen change must account for these patients’ unique
illness and treatment histories, and interventions should incorporate
tailored counselling and social and economic support.
Abbreviations: ART: Antiretroviral therapy; HIV: Human
immunodeﬁciency virus; IDI: In-depth interview; MSF: Médecins Sans
Frontières; PLHIV: People living with HIV
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Background
The scale-up of antiretroviral therapy (ART) in sub-Saharan Africa over the past 15 years has dra-
matically reduced HIV-related mortality and morbidity, with HIV-attributable deaths declining by
51% between 2004 and 2017 (UNAIDS, 2018). Eﬀorts are now focussed on achieving universal access
to ART with a view to controlling the epidemic, whereby people living with HIV (PLHIV) receive
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treatment as soon as they are diagnosed with HIV, and achieve sustained viral suppression through
adherence to an eﬀective regimen (WHO, 2015). This period in the HIV epidemic response is also
characterised by the rise of a burgeoning population of patients who are failing ﬁrst-line ART and
face diminished treatment options, typically requiring more expensive protease inhibitor-based
second-line ART (Cambiano et al., 2014; WHO, 2017). Virological failure rates amongst patients
on ﬁrst-line ART in treatment programmes across sub-Saharan Africa have been estimated at
24% after 12 months, and 33% after 24 months on treatment (Schuurman et al., 2010), and it has
been predicted that up to three million patients in sub-Saharan Africa will be receiving second-
line ART by 2020 (Estill et al., 2016).
With the rapidly increasing use of second-line regimens in sub-Saharan Africa, a new cohort of
patients who are experiencing antiretroviral treatment failure for a second time is also emerging. A
meta-analysis of treatment outcomes among patients on second-line regimens in resource-limited
settings demonstrated relatively high virological failure rates of 23% at 12 months and 27% at 24
months, with virological failure largely associated with poor adherence (Ajose, Mookerjee, Mills,
Boulle, & Ford, 2012). In sub-Saharan Africa, third-line ART regimens remain costly (14 times
more expensive than commonly used ﬁrst-line regimens) and are not yet readily available in most
settings, making second-line ART the last therapeutic option for most patients (WHO, 2017).
Despite a growing number of patients on second-line treatment regimens, there are limited interven-
tions tailored to their needs, partly reﬂecting the limited evidence base from qualitative studies per-
taining to these patients’ experiences and challenges they may face with adhering to advanced
treatment regimens (Barnett et al., 2013).
Before the widespread availability of ﬁrst-line ART in sub-Saharan Africa, PLHIV often experi-
enced progressive states of ill-health, causing substantial disruption to their lives and those of their
caregivers. Studies from this period have highlighted how the burden of caregiving and the associated
costs of illness of a family member could induce extreme poverty for the whole household, or result in
various strains on themain carer (Foster &Williamson, 2000; Kipp, Tindyebwa, Rubaale, Karamagi, &
Bajenja, 2007). During sustained or repeated periods of ill-health, other social relationships based on
reciprocity and mutual support may also be strained or disrupted, exposing individuals to illness-
related stigma and leaving them struggling to mobilise resources to improve their situation (Bury,
1982; Ssekubugu et al., 2018). Furthermore, the lived experiences of chronic illness can trigger pro-
found disruptions in a person’s understanding of their place in society, leading them to reconsider
their future plans and identity, particularly for diseases associatedwith disability or death (Bury, 1982).
The scale-up of ART led to the ‘Lazarus’ eﬀect amongst PLHIV who came close to death, but who
survived thanks to treatment availability (Pierret, 2007; Rofes, 1998; Trainor & Ezer, 2000; Whyte,
2014). This ‘biogeneration’ of PLHIV were marked by the shared experience of diagnosis and
near-death followed by initiation of eﬀective treatment (Whyte, 2014). Undergoing HIV testing
and initiating ﬁrst-line ART triggered changes in patients’ lives and outlook, as they recovered
from illness and were given a ‘second chance’ (Whyte, 2014) with re-shaped possibilities, opportu-
nities, social roles and relationships, and the emergence of new identities (Davies, 1997; Frank, 1993;
Hassin, 1994; Merten et al., 2010). For many PLHIV, these transformations brought a greater
appreciation for life, as well as enabling them to develop coping mechanisms, re-evaluate behaviours
around alcohol, drugs and sexual risks, and in some cases, adopt spirituality, religion, or participate
in community services (Alexias, Savvakis, & Stratopoulou, 2016). However, PLHIV are positioned as
part of an epidemic where life often cannot get ‘back to normal’ after receiving treatment (Shapiro,
Angus, & Davis, 1997): they may need to rebuild livelihoods, support a family alone, navigate inti-
mate relationships in the shadows of HIV, or face emotional hardship and perpetual stigma (Bon-
nington et al., 2017; Russell & Seeley, 2010; Wamoyi et al., 2017). As such, these ‘social rebirths’ are
rarely linear, are often fraught with challenges especially as the years progress, and are usually depen-
dent on PLHIV’s access to economic and social support, including supportive relationships with
their health providers (Ondenge et al., 2017; Russell et al., 2007; Russell & Seeley, 2010; Seeley & Rus-
sell, 2010).
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Much of the literature on how PLHIV experience social disruptions and transformations relates
to their HIV diagnosis, initiation of ART and their subsequent recovery (e.g. (Pierret, 2007; Seeley &
Russell, 2010; Whyte, 2014; Wringe, Renju, Seeley, Moshabela, & Skovdal, 2017)). Little research has
been undertaken to understand how PLHIV respond to treatment failure and the ways in which regi-
men change can shape their subsequent attitudes towards care-seeking. Although there may be par-
allels between patients’ experiences of initiating second- or third-line ART treatment, and the social
transitions that accompany recuperation from illness described in the early days of ART availability,
there may also be several diﬀerences: patients on second-line regimens will often have long treatment
histories and may have been living with an HIV diagnosis for well over a decade. Selection eﬀects will
also come into play whereby patients on second-line and third-line drugs are more likely to include
those who were unable to address adherence challenges whilst on previous regimens. Initiation of
second- or third-line ART may add to these challenges as a result of the greater complexity of the
drug regimens, including the pill burden and associated side-eﬀects, which persist, despite improve-
ments over recent years (WHO, 2016, 2018). On the other hand, patients who experience treatment
failure and eventually transition onto second or third-line regimens are ‘survivors’, and have often
undergone multiple experiences of declining health followed by ‘turning points’ (Shapiro et al., 1997)
where symptoms diminish after the initiation of a new, eﬀective regimen, potentially giving rise to
repeated or multiple social transformations (Russell & Seeley, 2010; Seeley & Russell, 2010).
In this paper, we explore patients’ lived experiences of treatment failure and the transition to
second- and in some cases, third-line antiretroviral therapy regimens in Kenya, Malawi and Mozam-
bique, with a view to informing interventions to support this growing cohort of patients.
Methods
Study context
We draw on qualitative data collected as part of a multi-country study that investigated treatment
failure among patients on second-line ART regimens in rural Malawi and Kenya, and urban Mozam-
bique. The study took place in three sub-Saharan African countries where Médecins Sans Frontières
(MSF) supports the Ministry of Health to run HIV care and treatment programmes: Chiradzulu in
rural south-eastern Malawi, Homa Bay, located on the banks of Lake Victoria in rural Kenya, and
Maputo, the capital city of Mozambique. The quantitative component of this study included a
cross-sectional survey to assess virological failure and associated drug resistance in all three sites
among patients receiving a boosted protease inhibitor-based second-line regimen for at least six
months following a history of treatment failure on a standard ﬁrst-line regimen (Schramm et al.,
2016). The key characteristics of the study settings and their HIV programmes are shown in
Table 1.
Data generation
Qualitative data generation took place between August 2016 and March 2017. Repeated in-depth
interviews (IDI) were conducted with PLHIV on second- or third-line ART. Two interviews per
participant were conducted, on average ﬁve days apart, in Dholuo, KiSwahili or English (Homa
Bay), Chichewa (Chiradzulu), and Portuguese or Changana (Maputo) by locally-recruited, non-
clinical, ﬁeldworkers with social science qualiﬁcations, matched to the participant’s gender. The
ﬁrst IDI lasted 25–60 minutes and aimed to develop rapport with the participants and covered
their lived experiences of illness and their treatment-taking journeys. The second IDI lasted 30–
75 minutes, and revisited the earlier topics as well as exploring patients’ knowledge and under-
standing of diﬀerent ART regimens, drug resistance and viral load results, and their views on treat-
ment and care services. All interviews with PLHIV took place in a private location outside the
clinic (such as a community building or school) depending on the participants’ preferences.
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Three participants were no-shows for the second interview and could not be contacted, whilst 5
participants requested to undertake both interviews on the same day, usually because of travel
or other commitments.
One-time IDIs were conducted with health workers across the three sites by the ﬁeld workers or
the lead author (RB) in English (with the exception of one IDI conducted in Portuguese in Maputo)
and took place in a private room within the health facilities. Topic guides with health workers elicited
their perceptions of the challenges faced by patients transitioning from ﬁrst to second or second to
third-line regimens, and their experiences of caring for these patients.
Observations took place in the HIV clinics during staﬀ meetings, group counselling sessions,
group education sessions and other activities. IDI were audio-recorded, transcribed and translated
(where necessary) into English. Fieldworkers wrote up interview summaries and recorded their
observations in study diaries, and discussed these during debrieﬁng and on-the-job training
sessions.
Sampling strategy
In each site, PLHIV were sampled for IDI from among those participating in the cross-sectional sur-
vey component of the study. Sampling took place between 17–20 months following the survey,
depending on the site. Additional inclusion criteria for the qualitative study included being 18
years of age or over. A purposive sampling strategy was used to ensure maximum diversity in
terms of viral load results during and following the cross-sectional survey, and ART regimen at
the time of the sampling (second-line, optimised second-line, third-line).
Table 1: Study setting characteristics.
Site Homa Bay Chiradzulu Maputo
HIV prevalence 24% (2012) 17% (2013) 17% (2010)
Start date of MSF/MoH
HIV intervention
2000 1997 2001
Health service setting County hospital District hospital and
10 health facilities
Referral level clinic
No. Patients (end 2016) 7341 36,500 2348
Year of second-line ART
introduction
2009 2005 2009
Prescribed second-line
regimen (2016)
Lopinavir-based
(twice-per-day)
Artazanavir
(once-per-day)
Lopinavir-based (twice-per-day)
No. Patients on second-
line ART (end 2016)
847 1780 1271
Year of third-line ART
introduction
2011 2015 2014
No. Patients on third-line
ART (end 2016)
26 17 37
Appointment schedule
(for second-and third-
line)
Monthly Bi-monthly Monthly
Interventions (second-line
patients):
Enhanced adherence
counselling
Monthly (regardless of VL
result)
Monthly (if high VL
result)
Monthly (if high VL result)
Viral load testing Every 12 months (and 6
months after regimen
change)
Every 6 months Every 12 months (and 6 months after regimen
change)
Diﬀerentiated model of
care for second-line
patients
N/A N/A 1. ‘Risk of treatment failure’ (clinician-lead and
counsellor-lead counselling) 2. Fast track
patient ‘clubs’ in case of undetectable VL (ART
reﬁll and group counselling)
Additional services Home visits, transport
reimbursements according
to need.
N/A Nutritional support, home visits according to
need.
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Across the three sites, 43 PLHIV on second- or third-line ART and 15 health workers participated
in the study (Table 2). PLHIV participants had a median age of 43 years, reﬂecting the fact that they
were generally highly treatment-experienced with a median time on ART of 9 years. The number of
male and female participants approximately reﬂected the gender distribution of second and third-
line patients in each setting. Among 18 participants receiving second-line ART, the median duration
on second-line ART was 2.8 years at the time of their interview. Among 25 participants who experi-
enced virological failure on second-line and changed regimens, their median duration on a modiﬁed
second-line regimen (simpliﬁed or optimised) was 12 months, and the median duration on third-line
regimens was 11 months, at the time of their interview.
Data management and analysis
Transcripts and notes were coded inductively by site, using NVivo11 software as an aid. Codes were
initially inductive and phenomenological, prioritising the meaning that participants themselves gave
to their experiences. A thematic analysiswas conducted, drawing on the principles of grounded theory,
whereby codes were raised to a conceptual level considering their underlying meaning and their inter-
relationship. Constant comparison between new codes and sites and existing codes took place, with
‘deviant’ cases, or those cases which ran counter to the emerging theory, also examined (Glaser &
Strauss, 1967). Data were collected until saturation was reached, meaning new themes were no longer
emerging from the analysis. Analyticmemoswere used to aid the process of deriving second and third-
order themes, and to compare across respondent types (e.g. patients with or without treatment failure
on second-lineART). Experiences over timewere also considered in order to reﬂect on the processes of
change including perspectives before and after treatment failure. Coding frameworks and analytical
memos were discussed regularly between the study researchers and ﬁeldworkers, ensuring that con-
sideration was given to the interpretation of categories that had local meanings attached.
Ethics
Ethical approval for the study was granted from the Kenya Medical Research Institute in Kenya
(KEMRI/RES/7/3/1), the National Health Sciences Research Committee in Malawi (1578), the
National Committee on Health and Bioethics in Mozambique (94/CNBS/2016) and the London
School of Hygiene and Tropical Medicine in the United Kingdom (11298).
Results
Three distinct themes emerged from the analysis reﬂecting the chronology of PLHIV’s lived experi-
ences of treatment failure and regimen change: ﬁrstly, social disruptions associated with ill-health
Table 2: Participant characteristics.
Group Kenya Malawi Mozambique Total
PLHIV VL <10001 Receiving second-line regimen 5 4 4 13
VL ≥10002 Stayed on second-line regimen 0 2 3 5
Switched to simpliﬁed/optimised second-line
regimen
6 2 2 10
Switched to third-line regimen 5 5 5 15
Female 10 7 8 25
Male 6 6 6 18
Health Clinical staﬀ 2 4 2 8
workers Counsellors and support
staﬀ
3 1 3 7
Total\ 21 18 19 58
1at most recent viral load test and ∼12 months before IDI;
2at viral load test ∼12 months before IDI.
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related to ﬁrst-line treatment failure; secondly, social transformations that occurred following a
switch to a new treatment regimen; and thirdly PLHIVs’ engagement with new treatment regimens
following these transformations.
‘I was about to die’: living with treatment failure
When recalling their experiences of failing ﬁrst-line ART, many participants referred to the resur-
gence of HIV illnesses. For some participants, this fear was palpable through their feelings of cer-
tainty that they would not survive, leading them to question the relevance of continued drug-taking:
I was sick, doctor, I was very sick, and I couldn’t even stand up, I was not even talking. Now my heart was still
calculating, I was thinking that: why should I now take these drugs when I was about to die… ? [Woman receiv-
ing second-line ART, Kenya]
Others recalled the circumstances that may have contributed to ﬁrst-line treatment failure, and
some acknowledged the emotional burden of living with HIV, or earlier denial of their HIV status
which was overcome as ill-health came to the forefront of their daily lives:
There was a time I stopped taking them (ART). I said to myself ‘why do I have this illness? I would rather die.’
But later I realized that, I just can’t think that way, and then I kept on taking pills again. Why did you feel this
way? I did not believe I have HIV [Man receiving second line ART, Mozambique]
Other participants recalled having endured long stays in hospital, or with relatives, and the sig-
niﬁcant toll that these illnesses had taken on their social lives and economic activities, with some
having to completely change their lifestyle and jobs. For some participants, this change of lifestyle
could be less enjoyable, or represented a constant reminder of the fact that they were unwell:
Ok, can you talk about your daily routine?… as I am ill, as soon as I take my meal, I generally go to bed, I get
up and watch TV, I do nothing at all.What did you used to do before you were sick? I used to do the cleaning
in the house…Where do you usually go to chill out, especially at the weekends? As I am sick, I do not enjoy,
I just stay home. When I feel better I only go out to parties where I am invited to. I was a dancer, I used to dance
at parties, and weddings. [Man receiving second-line ART, Mozambique]
Periods of illness were often prolonged as some patients experienced delays in being switched to
second-line ART, extending the duration and consequences of social and economic disruptions
caused by treatment failure.
They said that the treatment I was taking was over; it was not working in a good way. But that was when I was
sick in hospital because of tuberculosis .… it took me a while to get those pills and when they changed, I felt
ﬁne. [Man receiving third-line ART, Mozambique]
In this context, treatment failure often prompted reﬂection or provoked blame among PLHIV as
they struggled to ﬁnd meaning to their predicament, as one Kenyan health worker explained:
At times they blame themselves, at times they blame it on drugs and at times it is blamed on the health care
workers. [Health worker, Kenya]
‘My drugs shaped my lifestyle’: new treatment brings social transformations
After experiencing life-threatening illnesses due to treatment failure, many patients felt they were
given a second chance at life when switched to a second-line regimen that would provide eﬀective
treatment. This was even more notable for patients who had switched to third-line ART and were
acutely aware of their limited treatment options, as one Malawian man explained:
To tell the truth, I felt I was going to go back home and wait for my death. So, when I heard about the research
for third-line I saw it as a second chance. So I joined and I was given the drugs. They told me there was not any
other drugs and no fourth-line, so I was glad it worked otherwise I would be dead now. [Man receiving third-
line ART, Malawi]
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Changing treatment catalysed transformations for many participants as they reﬂected on earlier
‘mistakes’ that had contributed to poor adherence, and made changes or found compromises in their
lives to accommodate more regular pill-taking. For example, some participants reported how they
could only accommodate daily pill-taking routines through changing their source of livelihood,
which some participants appeared to accept and even embrace.
..my drugs shaped my lifestyle and it shaped it permanently… I had to organize my duties and my responsi-
bilities in accordance to my time of taking drugs. I was an ardent ﬁsherman, but nowadays I am an ardent gar-
dener [Man receiving second-line ART, Kenya]
However, other participants expressed regret and reluctance when faced with the need to change
their livelihoods in order to accommodate the requirements of regular treatment-taking or appoint-
ment attendance. In some cases, this prompted regret over their past attitudes or behaviours towards
their drugs, expressed through self-blame and the sense of an opportunity lost.
Now I am limited, I cannot go to South Africa. That’s where I used to earn the living… I can only earn the living
around here in the city waiting for the 14th to go and to reﬁll the pills… because I am needed at the hospital for
tests… and this aﬀects me…On the ﬁrst line, after having felt better, I went abroad to work. That’s where I
ruined everything. I stayed two years without taking them [Man receiving second-line ART, Mozambique]
Other changes that occurred to participants’ lives as a result of incorporating regular pill-taking
were often perceived positively. Some participants described themselves as being more appreciative
of treatment than in the past, while others reported overcoming community stigma, including dis-
closing their HIV status to other people, or overcoming denial in order to stay alive to bring up their
children and fulﬁl their social roles as a mother. Nevertheless, these transformations sometimes
required interventions from family members or health workers, often desperate for their relatives
or clients to respond to this ‘second chance’ at life. One participant recounted how her husband,
who was her treatment supporter, and also on ART, helped her through her denial:
My CD4 decreased and viral load went up to 2000 copies. So that’s when they [the health workers] called my
husband, they said ‘it’s better you talk to your wife, because your wife is going to die’. And I was about to die. So
then, in the hospital, my husband talked to me, I swore right there ‘never again’. From that day, I was going to
start taking the pills. And I started taking them normally, no problem…He would say ‘ … I am pleading. Con-
tinue and never give up! Take the pills, because we have these children here to look after, they still need us a lot,
especially the little one… look at your baby, and think: between the pill and the baby, what do you want?’
[Woman recently switched to third-line ART, Mozambique]
Some patients reported changing their attitudes towards their intimate relationships in the wake
of treatment failure: several men declared they had reduced ‘womanising’ and some women divorced
husbands that they believed to be promiscuous.
They [health workers] said the drugs were failing, the viruses were still multiplying… I said that sincemy husband
refuses to use condoms it was better for me to dump him. [Woman recently switched to third-line ART, Malawi]
In some cases, these changes were encouraged by health workers through their counselling of the
patients, where they often attributed treatment failure to high-risk sexual behaviours (through ‘re-
infection’) rather than as a result of sub-optimal ART adherence, and thereby shifted responsibility
for high viral load results away from the patient’s own treatment-taking:
Mostly of course those with high viral loads we send them to the counsellors to discuss with the patient in terms
of how she sees the husband and if he is faithful to you or do you trust him… ? Re-infection comes because
husbands may go to sleep with other women and then come to sleep with the wife who has maybe been trying
to take medicine properly… then he re-infects the poor lady [Health worker]
‘Nowadays we are used to it’: maintenance or relapse of social transformations
Although many participants expressed their commitment to more regular pill-taking with their new
ART regimen, some adherence challenges were not always easily surmountable. Changes to
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behaviours and lifestyles could be precarious and diﬃcult to enact and sustain over time, such that
initial, good intentions could sometimes fade as one man explained:
Sometimes when things start, they start nicely. When a person buys a car, he thinks about cleaning it before he
leaves. It is like pills, a person takes them regularly on the ﬁrst days, then he says ‘ahh I will take them tomor-
row’. [Man receiving second-line ART, Mozambique]
A ﬂuctuating sense of hope was also common among participants who, on the one hand often felt
a sense of optimism regarding the future following regimen change, but on the other had already
experienced the psychological burden of sustaining treatment:
Okay, I have accepted to take the drugs, and again I have accepted that I am sick and I have started a new walk.
Now, what can I do to make me continue going for care without losing hope? In my case, I have accepted to
come for care, but sometimes maybe I can start losing hope: now what is it that can keep me moving and going
on so that I don’t go backwards? [Woman receiving third-line ART, Kenya]
However, other participants described how they found it progressively easier to adhere to their
drugs over time, as they became more ‘experienced’ with taking their treatment, more used to attend-
ing HIV clinics and more familiar with treatment messages. Furthermore, in each of the settings,
patients mentioned how the counselling helped them to understand the causes of treatment failure,
allowing them to potentially address the problems that had caused it. Patients often cited building up
a strong personal rapport with counselling staﬀ, or becoming engaged with group counselling activi-
ties which encouraged them to make transformations in their lives that were more conducive to
regular pill-taking. In some cases, participants attributed counselling as the main reason that they
were able to overcome emotional and psychological struggles that had undermined their previous
engagement in care, as one Kenyan woman explained:
Only one of the twins survived… I had a lot of thoughts, I stopped taking drugs for two years. [name of coun-
sellor] kept on teaching us, she taught me… I joined the support group and you could hear people had chal-
lenges more than what you are going through, I listened to them then I gathered courage and started taking
drugs. [Woman receiving second-line ART, Kenya]
Over the years, many patients reported building resilience to community stigma:
Earlier I used to feel bad, but nowadays even the people who used to walk tip toe when going to take the drugs so
that you don’t see them. So someone can laugh at you today… tomorrow you are in the queue with them!
Nowadays we are used to it even if people talk. [Woman receiving second-line ART, Kenya]
They cared less about what other people thought, and may have disclosed their status to their
partners, families or in some cases publicly. This often facilitated pill-taking inside households or
workplaces, as family members could remind them to take their doses, or support them emotionally.
Some participants in Maputo described how maintaining their transformed lives was facilitated
through access to diﬀerentiated models of care oﬀered to patients on second-line treatment with
undetectable viral loads. Patient clubs with fast-track reﬁlls, for instance, were appreciated given
they allowed participants to re-enter employment or re-engage in other activities that some had
stopped following treatment failure:
Clubs save time and we do not have to wait long in the pharmacy, and check-up…we no longer have to ask for
permission at work to go to hospital… [Man receiving second-line ART, Mozambique]
However, other patients risked not being able to maintain their renewed desire to adhere to their
drugs given the persistence of multiple and interrelated social, economic, health system and medi-
cation challenges that had previously undermined their adherence on ﬁrst-line regimens. Once
initiated on second-line ART, there were usually a greater number of pills, a twice-daily prescription,
and more signiﬁcant side eﬀects, all of which could conﬂict with participants’ work or family obli-
gations. Patients navigated these challenges in diﬀerent ways, sometimes modifying their dosing
schedule, to cope with side-eﬀects.
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I used to take my drugs once a day, I decided it on my own because I could hear some people say that the drugs
can be taken once…when I was walking I felt some dizziness and that was preventing me from going to the
garden, that is how I started taking drugs once (per day) Did you tell the doctor? … when he asked how am
taking the drugs I said 8 in the morning and 8 in the evening. I never told him that am taking the drugs once.
[Woman receiving third-line ART, Kenya]
This account also illustrates how some participants navigated diﬀerent sources of information,
from other PLHIV as well as health workers, in order to make their treatment-taking decisions,
which they may then choose to conceal from health workers.
For other patients, challenges that they had experienced whilst on ﬁrst-line ART remained unad-
dressed and continued to blight their eﬀorts to take their pills regularly, particularly those that were
related to structural issues such as poverty.
My social position is not good as I am not working, I sometimes have appetite of eating fruits, many other
things. Nonetheless I can’t aﬀord: the same diﬃculties I used to go through when I was on the ﬁrst line
[ART]. Regarding diﬃculties, nothing has changed. [Man receiving second-line ART, Mozambique]
Discussion
This study explored the narratives of biographical disruptions and social transformations in the
accounts of PLHIV who had experienced treatment failure prior to being transitioned onto
second-, and in some cases, third-line treatment regimens, in one urban and two rural African set-
tings. We found that when faced with ill-health as a result of treatment failure (typically on ﬁrst-line
regimens), PLHIV often gave up hope, fearing an imminent death, mirroring the despair that was
often observed among PLHIV in the era prior to widespread ART availability (Pierret, 2007; Trainor
& Ezer, 2000; Whyte, 2014). Prolonged illnesses due to delays in switching regimens could exacerbate
the suﬀering and despair of PLHIV, although this may be improving with recent scale-up of routine
viral load monitoring. Being transitioned onto a more eﬀective treatment regimen often restored
hope and engendered a sense of optimism for these patients. Our ﬁndings support calls for timely
regimen switching for patients with treatment failure and align with those of other researchers
who have identiﬁed hope as a central element of patients’ experiences of life on ART (Nixon
et al., 2018; Rhodes, Bernays, & Terzić, 2009), conﬁrming the importance of interventions that
help to sustain patients’ hope and optimism for promoting their engagement with HIV treatment
programmes (Bernays, Rhodes, & Barnett, 2007; Nixon et al., 2018).
Initiation of second- or third-line regimens was often also experienced by patients as an oppor-
tunity for redemption and a second chance to try and adhere to the strict behavioural codes that were
seen as necessary for adequate pill-taking. Other scholars have noted similar responses from PLHIV
after witnessing the death of a peer or loved one which may also act as a trigger to overcome denial or
adherence challenges (Skovdal et al., 2017). Our participants were often able to make substantial
changes to their working arrangements or social circumstances in order to address previous chal-
lenges that had undermined their ability to take their drugs as prescribed. Several researchers
have also noted how social relationships may be modiﬁed, or behaviours re-evaluated among people
living with chronic illnesses including HIV, often leading to the development of new identities and
coping mechanisms (Davies, 1997; Frank, 1993; Hassin, 1994; Merten et al., 2010; Russell & Seeley,
2010; Seeley & Russell, 2010). In accord with previous studies, our ﬁndings suggest that the ability of
PLHIV to eﬀectively incorporate these changes into their biographies with a sense of progression,
rather than disruption, is likely to be paramount to sustained engagement to treatment in the
long-term (Alexias et al., 2016; Wekesa & Coast, 2013).
A sense of regret, remorse and self-blame were commonly expressed among our participants as
they reﬂected on the circumstances that led to their treatment failure, particularly when they con-
sidered that second- or third-line treatment regimens would require additional sacriﬁces or compro-
mises to their lifestyle. Other researchers have also shown that PLHIV often blame themselves for
dis-engaging from care, and that this sense of guilt and fault need to be carefully navigated by health
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care workers as they move forward in their treatment journeys (Layer et al., 2014). In addition, the
precarity of the social transformations that accompany regimen change that we observed echo the
ﬁndings in Russell and Seeley’s research in Uganda among individuals who initiated ﬁrst-line
ART following HIV-related illnesses (Russell & Seeley, 2010; Seeley & Russell, 2010) and recall
the complexity of achieving sustained engagement with HIV care and treatment in the context of
pervasive stigma and challenging social circumstances (Ondenge et al., 2017; Skovdal et al., 2017;
Stern, Colvin, Schutz, Burton, & Meintjes, 2017; Wamoyi et al., 2017). Other researchers have
also noted apparent contradictions or paradoxes in the experiences of patients who have very
long treatment histories, whereby optimism and hope often co-exist alongside new challenges that
arise from sustained treatment-taking, and which may risk undermining treatment-taking (Nixon
et al., 2018).
Our ﬁndings chart various unique challenges and supportive inﬂuences for maintaining a com-
mitment to treatment over time amongst these patients. In line with other studies, we found that
patients’ transformations were closely linked to their social and economic circumstances which
are often gendered (Merten et al., 2010; Russell & Seeley, 2010; Seeley & Russell, 2010). As such,
economic as well as social support may help some patients to better cope through periods of liveli-
hood disruptions arising from their treatment and care routines.
The themes that emerged from our analysis were very similar across the three sites, likely reﬂect-
ing the fact that all three programmes were supported by MSF and therefore provided similar ser-
vices and standard of care to second- and third-line patients. Tailored and patient-centred
counselling proved valuable to many participants in our study as they transitioned through regi-
men-changing processes. Counselling interventions should recognise that patients who experience
treatment failure may need support to prepare for transitioning onto second- or third-line regimens,
including messages and skill development tailored to this cohort in order for them to understand and
address the underlying causes for treatment failure. Furthermore, the needs of patients on second-
line treatment are likely to be ﬂuid, and those who struggle to address previous challenges to adher-
ence may need more counselling support including access to support groups to trigger social changes
in their lives that are conducive to more regular pill-taking. However, counselling is poorly sup-
ported or in decline in many sub-Saharan African settings. In the three countries included in this
study there is no dedicated counselling cadre within the Ministry of Health workforce and counsel-
ling is left to clinical staﬀ unless services are provided by partner organisations. As a result, these
needs may go unmet unless greater national-level guidance and commitment to quality patient-
centred counselling is forthcoming.
Our results also showed that patient clubs were important in catalysing or maintaining patients’
‘transformations’. There is a growing recognition of the need for patient clubs oﬀered through diﬀer-
entiated care strategies, including for patients on second-line regimens (ICAP, 2017). National
guidelines on diﬀerentiated care in Kenya, Malawi and Mozambique are starting to make provisions
for patients on second-line regimens, although their implementation is not yet widespread (Grims-
rud, Barnabas, Ehrenkranz, & Ford, 2017; Ministry of Health Kenya, 2015; Ministry of Health
Malawi, 2016).
These ﬁndings need to be considered in light of various limitations that are inherent to qualitative
studies exploring experiences of adherence to ART. Patients may have overstated the signiﬁcance of
‘transformations’ if they felt pressure from health services to ‘repent’ previous mistakes and justify
their access to scarce regimens through exemplary adherence behaviour. Furthermore, although
researchers were non-clinical, their association with a medical organisation may have inﬂuenced
the participants’ accounts. We tried to mitigate this by carrying out extensive ﬁeldworker training,
and by conducting repeat interviews with PLHIV wherever possible in order to build rapport and
trust over time. Similarly, we used ‘vignettes’ a tool that allowed PLHIV to explain their adherence
experiences and challenges through a hypothetical third person which may allow them to speak more
freely about socially undesirable behaviour (Gourlay et al., 2014). Only patients who were currently
engaged in HIV care were recruited into the study, and as such, the views of patients with the greatest
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challenges with respect to receiving care, including those who did not manage to successfully tran-
sition to second- or third-line regimens would not have been captured.
An important strength of our study was our ability to draw on data from three diﬀerent study
sites, enabling us to document the similarity in the experiences of patients across diverse settings.
To our knowledge, this is one of the ﬁrst published qualitative studies among patients on second-
and third-line treatment regimens and is valuable in providing insights into the challenges that
may undermine the eﬀectiveness of these regimens in these three sub-Saharan African settings.
These ﬁndings are particularly timely as current eﬀorts to scale up routine viral load monitoring
and reduce the prices of second-line antiretroviral therapy regimens are likely to result in several
million patients being transferred from ﬁrst to second-line regimens over the coming decade (Estill
et al., 2016). There is a short window of opportunity to learn from the experiences of patients on
second-line treatments in order to design interventions that are likely to maximise the duration
and eﬀectiveness of increasingly wide-spread salvage regimens.
Conclusion
In conclusion, we found that patients on second- and third-line treatment regimens may initially
experience transformations regarding social and economic aspects of their lives and their attitudes
towards treatment, in many cases allowing re-engagement with treatment. However, the risk of
relapse may be high unless prior challenges to adherence are addressed. Interventions should recog-
nise the unique experiences of this growing population and deliver psychosocial support, treatment
messages and models of care that are tailored and aimed towards promoting transformations and
sustaining changes. This can aid in prolonging the life-span of second and third-line regimens.
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